REGN Stock Forecast: Regeneron Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$921
−0.12% on the day

The 28 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. hold a median 12-month price target of $1,000 — +8.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 97 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$95.2B
Ticker Nerd rank
97/ 100
Median analyst target
$1,000
Analysts covering
28
Revenue$4.3B+16.7% y/y
Operating income$1.4B
Net income$1.3B
Free cash flow$521.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.5%
1M
+14.2%
YTD
+19.9%
1Y
+25.6%
From 52W high
−5.3%
From 52W low
+53.7%
$599
$972
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Regeneron Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
97/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Revisions
96
Volatility
95
Value
95
Quality
83
Growth
78
Issuance
77
Accruals
34

Momentum (96): The shares have been drifting up relative to others.

Accruals (34): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

REGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on REGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$600$700$800$900$1,000$1,100$1,200Jan 26Apr 26Jul 26Oct 26REGNHigh $1,175Median $1,000Low $812

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
19
Buy
9
Hold
0
Sell
$812
Low
$1,000
Median
$1,175
High

The green dot is the last close — the median target sits +8.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 19 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
17 Nov 2026BarclaysMaintainsOverweight$917 → $1,075
2 Nov 2026B of A SecuritiesMaintainsBuy$908 → $1,030
2 Nov 2026BairdMaintainsNeutral$761 → $875
2 Nov 2026BernsteinMaintainsMarket Perform$756 → $812
2 Nov 2026Canaccord GenuityMaintainsBuy$922 → $1,175
2 Nov 2026Cantor FitzgeraldMaintainsOverweight$795 → $980
2 Nov 2026Evercore ISI GroupMaintainsOutperform$900 → $1,075
2 Nov 2026GuggenheimMaintainsBuy$1,030 → $1,100
2 Nov 2026Leerink PartnersMaintainsMarket Perform$835 → $997
2 Nov 2026Morgan StanleyMaintainsEqual-Weight$779 → $855
2 Nov 2026RBC CapitalMaintainsSector Perform$810 → $913
2 Nov 2026Truist SecuritiesMaintainsBuy$780 → $982
2 Nov 2026Wells FargoMaintainsEqual-Weight$750 → $925
31 Oct 2026JP MorganMaintainsOverweight—
30 Oct 2026CitigroupMaintainsNeutral$740 → $825
30 Oct 2026JP MorganMaintainsOverweight$950 → $1,050
28 Oct 2026Canaccord GenuityMaintainsBuy$875 → $922
21 Oct 2026TD CowenMaintainsBuy$960 → $980
19 Oct 2026Piper SandlerMaintainsOverweight$854 → $865
15 Oct 2026UBSUpgradeBuy$660 → $978

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for REGN.

Market Radar

This page is one stock. Monday covers all of them.

REGN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

REGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Regeneron Pharmaceuticals, Inc. returned +25.6% against +6.9% for the S&P 500, dividends included.

REGN vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Jan 26Apr 26Jul 26Oct 26REGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

REGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+29.7%
Analysts raising
23
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
20.4×

Cheaper than 44% of US stocks

Price / sales
5.6×

Cheaper than 19% of US stocks

Price / book
2.8×

Cheaper than 33% of US stocks

EV / EBITDA
15.2×

Cheaper than 33% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
33.5%

Higher than 68% of US stocks

Gross margin
86.6%

Higher than 95% of US stocks

Operating margin
30.4%

Higher than 88% of US stocks

Net margin
28.5%

Higher than 87% of US stocks

Returns & dividend
Return on equity
14.9%

Higher than 74% of US stocks

Return on assets
7.6%

Higher than 86% of US stocks

Dividend yield
0.4%

Higher than 6% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Regeneron Pharmaceuticals, Inc. has a market value of $95.2B and an enterprise value of $85.8B.

  • Revenue in the twelve months to 30 June 2026: $15.5B. The latest quarter grew 16.7% year on year.

  • Net income over the same four quarters: $4.3B, a 27.9% net margin.

  • Diluted earnings per share, trailing twelve months: $40.46.

  • Free cash flow in the twelve months to 30 June 2026: $3.6B, after $920.9M of capital spending.

  • Regeneron Pharmaceuticals, Inc. spent $3.9B on share buybacks and $378.5M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 103.1M.

  • Trailing P/E: 20.4×; forward P/E: 12.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.41%, paying out 8% of earnings.

  • Regeneron Pharmaceuticals, Inc. employs 15,410 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

REGN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
REGNRegeneron Pharmaceuticals, Inc.$95.2B97
MRNAModerna, Inc.$77.9B84
VRTXVertex Pharmaceuticals, Inc.$130.7B61
RPRXRoyalty Pharma Plc$39.4B97
RVMDRevolution Medicines, Inc.$33.6B56
INSMInsmed, Inc.$30.9B76
ROIVRoivant Sciences Ltd.$27.7B83

Take a look at REGN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Regeneron Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about REGN

What is the REGN stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. have a median 12-month price target of $1,000, with estimates ranging from $812 to $1,175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is REGN stock a buy right now?

Of the 28 analysts covering Regeneron Pharmaceuticals, Inc., 19 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Regeneron Pharmaceuticals, Inc. 97 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank REGN?

As at 21 Nov 2026, Regeneron Pharmaceuticals, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will REGN stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +8.5% from the last close, and Ticker Nerd's factor model ranks Regeneron Pharmaceuticals, Inc. 97 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the REGN stock forecast for 2030?

No analyst covering Regeneron Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $812 to $1,175 over the next 12 months.

How has REGN stock performed over the past year?

Regeneron Pharmaceuticals, Inc. returned +25.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Regeneron Pharmaceuticals, Inc. do?

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders.

Company

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders. The company is known for combining laboratory research, clinical development, and in-house manufacturing to advance biologic therapies and antibody-based medicines. Regeneron also works on product candidates across multiple therapeutic areas, supporting a broad drug pipeline alongside its marketed medicines. Regeneron Pharmaceuticals, Inc. plays an important role in the healthcare market through its focus on specialty therapies designed for complex and often chronic medical conditions.

CEO Dr. Leonard S. Schleifer M.D., Ph.D. · 15,410 employees · United States · https://www.regeneron.com